Yes. The promising research seam is real—but the “magic” is probably not another prototype, projection, or robustness loss.

Your results show:

- The representation contains the information: full supervision reaches 83.53% AUROC.
- Few-shot adaptation cannot recover it: 10-shot reaches 60.85%.
- Reducing SMS does not improve recognition: several methods become invariant by becoming less adaptive.
- Static local matching also fails, because a patch still does not reveal whether it represents pneumothorax, a tube, or correlated anatomy.

That makes this primarily an identification problem, not a representation problem. See [test-9.pdf](</Users/arnurartykbay/Downloads/test-9.pdf>).

## My strongest idea: TRACE

**Temporal Residuals for Anatomy-grounded Counterfactual Evidence**

The key principle is:

> Do not learn a hard disease from what positive images resemble. Learn it from what changes when the disease appears or resolves—while devices and other findings do not.

A static dataset may make pneumothorax and chest tubes observationally inseparable. No clever loss can solve that if they always co-occur. Longitudinal studies supply natural interventions:

- Pneumothorax appears before tube insertion.
- Pneumothorax resolves while the tube remains.
- A tube is inserted or removed while the pathology is stable.
- Neither changes in control pairs.

Those transitions provide the missing variation needed for identification.

### How TRACE would work

1. **Build longitudinal anatomical pairs**

   Use consecutive studies from the same training patient. Register corresponding lung and pleural regions and compute native-resolution RAD-DINO token changes.

   Chest ImaGenome already contains more than 670,000 localized comparison relations between sequential examinations, making this unusually feasible. [PhysioNet Chest ImaGenome](https://physionet.org/content/chest-imagenome/1.0.0/)

2. **Learn a dictionary of transition atoms**

   Factor each temporal residual into:

   \[
   \Delta z
   \approx
   V_{\text{pathology}}\alpha_p+
   V_{\text{device}}\alpha_d+
   V_{\text{acquisition}}\alpha_s.
   \]

   Enforce:

   - onset–resolution antisymmetry;
   - anatomy consistency;
   - separation of device-only and pathology-only transitions;
   - sparse explanations;
   - temporal reversal and reconstruction consistency.

   Importantly, do not subtract a tube direction. Fit a generative factorization in which pathology and device can coexist.

3. **Turn a hard disease into a sparse diagnostic program**

   At few-shot time, the disease description and \(K\) supports select a small combination of learned atoms:

   - pleural line;
   - absent peripheral lung markings;
   - deep sulcus sign;
   - expected pleural anatomy;
   - alternative manifestations for AP versus PA images.

   Supports estimate perhaps 5–20 atom weights—not a noisy 768-dimensional classifier.

4. **Marginalize the nuisance**

   Score a query with a likelihood ratio:

   \[
   s_c(q)=
   \log
   \frac{\sum_d p(E_q\mid y_c=1,d)\,p(d)}
        {\sum_d p(E_q\mid y_c=0,d)\,p(d)}.
   \]

   Here \(E_q\) is localized evidence and \(d\) is the latent device state. The method asks whether pathology evidence exists after considering every plausible device explanation.

5. **Predict identifiability, not only disease**

   TRACE should return an **Interventional Identifiability Score** for each class based on:

   - availability of disease-only transitions;
   - consistency of anatomical change atoms;
   - separation from device-only transitions;
   - support posterior uncertainty;
   - number of independently activated witnesses.

   A class with insufficient independent transitions is reported as genuinely non-identifiable, together with the most valuable additional example to label.

## Why this is potentially a major contribution

Recent work covers the individual ingredients:

- Semantic feature decomposition and test-time adaptation have already been applied to few-shot CXR diagnosis, reporting roughly 3–5% AUROC gains. [WACV 2026 paper](https://openaccess.thecvf.com/content/WACV2026/html/Mahawar_Test-Time_Adaptation_through_Semantically-guided_Feature_Decomposition_for_Few-shot_Chest_X-ray_WACV_2026_paper.html)
- Temporal CXR models learn disease progression, but primarily for progression classification or report generation. [TempA-VLP](https://openaccess.thecvf.com/content/WACV2025/html/Yang_TempA-VLP_Temporal-Aware_Vision-Language_Pretraining_for_Longitudinal_Exploration_in_Chest_X-ray_WACV_2025_paper.html), [ProTrans](https://arxiv.org/abs/2606.15938)
- Causal concept bottlenecks model pathology-to-finding relationships, but use predefined diseases and fully trained concept predictors rather than few-shot novel-class induction. [XpertCausal](https://arxiv.org/abs/2605.07785)

The apparently open intersection is:

> **Using longitudinal natural interventions to learn reusable causal evidence atoms, then composing them to recognize a hard novel disease from a few static examples while marginalizing treatment devices.**

That is much more defensible than claiming another debiased prototype.

## Run these kill tests first

Before building TRACE, run two inexpensive experiments.

1. **Covariance-aware few-shot baseline**

   Estimate covariance from all unlabeled training embeddings and test shrinkage LDA:

   \[
   w_K=(\widehat\Sigma+\lambda I)^{-1}
   (\widehat\mu_+-\widehat\mu_-).
   \]

   If this jumps substantially above 60.85%, much of the problem is simply anisotropic high-dimensional estimation.

2. **Temporal identifiability pilot**

   For pneumothorax/device, count and test four transition groups:

   - disease changes, device stable;
   - disease stable, device changes;
   - disease resolves, device remains;
   - both stable.

   Train only a linear model on registered RAD-DINO transition tokens. Continue only if it:

   - separates disease change from stable disease at AUROC ≥ 0.75;
   - has device-only false activation near chance;
   - localizes to plausible pleural regions;
   - improves the existing 3-shot result by at least 5 AUROC points while keeping SMS ≤ 0.6.

For a strict few-shot claim, temporal pretraining must use training patients only, mask the held-out target name and synonyms, and use no target-specific labels beyond the \(K\) supports.

My honest assessment: **TRACE is high-risk, but it attacks the actual impossibility boundary exposed by your experiments.** The valuable scientific result would be either a large hard-class gain or a principled demonstration of when few-shot disease identification is impossible without temporal or interventional variation. Both are stronger stories than another small SMS improvement.